Article

Rational Discovery of Dual-Action Multi-Target Kinase Inhibitor for Precision Anti-Cancer Therapy Using Structural Systems Pharmacology

2018-11-07

Abstract excerpt

Although remarkable progresses have been made in the cancer treatment, existing anti-cancer drugs are associated with increasing risk of heart failure, variable drug response, and acquired drug resistance. To address these challenges, for the first time, we develop a novel genome-scale multi-target screening platform 3D-REMAP that integrates data from structural genomics and chemical genomics as well as synthesize...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: c97d9226-0da4-59b8-9e56-4bccb0da5be4
DOI: 10.1101/465054

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Rational Discovery of Dual-Action Multi-Target Kinase Inhibitor for Precision Anti-Cancer Therapy Using Structural Systems PharmacologyDOI 10.1101/465054Read

Polypharmacology is an enduring and nearly universal property of kinase inhibitorsSemantic proximity Read

Combined kinome inhibition states are predictive of cancer cell line sensitivity to kinase inhibitor combination therapiesSemantic proximity Read

A cancer pharmacogenomic screen powering crowd-sourced advancement of drug combination predictionSemantic proximity Read

A brief survey on computational approaches to reveal drug and disease associations.Semantic proximity Read

Computational pharmacogenomics screen identifies synergistic statin-compound combinations as anti-breast cancer therapiesSemantic proximity Read

Deep characterization of cancer drugs mechanism of action by integrating large-scale genetic and drug screensSemantic proximity Read

Bioinformatics-driven discovery of rational combination for overcoming EGFR-mutant lung cancer resistance to EGFR therapy.Semantic proximity Read

An Integrative Drug Repurposing Pipeline: Switching Viral Drugs to Breast Cancer.Semantic proximity Read

Death by a Thousand Cuts – Combining Kinase Inhibitors for Selective Target Inhibition and Rational PolypharmacologySemantic proximity Read

Integrated Single-Dose Kinome Profiling Data is Predictive of Cancer Cell Line Sensitivity to Kinase InhibitorsSemantic proximity Read

Computational pharmacogenomic screen identifies drugs that phenocopy dipyridamole and potentiate anti-breast cancer activity of statinsSemantic proximity Read

Kinome-centric pharmacoproteomics identifies signaling pathways underlying cellular responses to targeted cancer drugsSemantic proximity Read